CYCN Cyclerion Therapeutics, Inc.

Nasdaq cyclerion.com


$ 1.38 $ 0.03 (2.21 %)    

Monday, 17-Nov-2025 15:08:15 EST
QQQ $ 602.34 $ -5.20 (-0.85 %)
DIA $ 466.18 $ -5.48 (-1.16 %)
SPY $ 664.83 $ -6.26 (-0.93 %)
TLT $ 89.11 $ 0.22 (0.25 %)
GLD $ 370.86 $ -4.31 (-1.15 %)
$ 1.39
$ 1.38
$ 1.38 x 1
$ 1.41 x 1
$ 1.35 - $ 1.42
$ 1.27 - $ 9.47
83,856
na
5.46M
$ 1.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 03-04-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 03-05-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 07-28-2023 06-30-2023 10-Q
11 05-12-2023 03-31-2023 10-Q
12 03-22-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 07-29-2021 06-30-2021 10-Q
19 04-30-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-03-2020 06-30-2020 10-Q
23 05-04-2020 03-31-2020 10-Q
24 03-12-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-12-2019 06-30-2019 10-Q
27 05-13-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outst...

Core News & Articles

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their ...

 cyclerion-therapeutics-says-under-license-agreement-mit-eligible-for-up-to-44m-in-milestone-payments

-SEC Filing

 cyclerion-announces-license-agreement-with-mit-to-relaunch-advancing-phase-2ready-treatment-for-resistant-depression

– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT L...

 cyclerion-therapeutics-q2-eps-011-up-from-053-yoy-sales-9600k

Cyclerion Therapeutics (NASDAQ:CYCN) reported quarterly losses of $(0.11) per share. This is a 79.25 percent increase over loss...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION